Role of immune activation in HIV pathogenesis

Current HIV/AIDS Reports

Volumn 4, Issue 1, 2007, Pages 42-47

  Hunt, Peter W ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 2; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATHOGENESIS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

EID: 34147190899     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-007-0007-8     Document Type: Review

References (61)

1. Finkel TH, Tudor-Williams G, Banda NK, et al.: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1:129-134.
2. Groux H, Torpier G, Monte D, et al.: Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331-340.
3. Meyaard L, Otto SA, Jonker RR, et al.: Programmed death of T cells in HIV-1 infection. Science 1992, 257:217-219.
4. Silvestri G, Sodora DL, Koup RA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
5. Harper ME, Marselle LM, Gallo RC, Wong-Staal F: Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A 1986, 83:772-776.
6. Ascher MS, Sheppard HW: AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988, 73:165-167.
7. Papagno L, Spina CA, Marchant A, et al.: Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004, 2:E20.
8. Doisne JM, Urrutia A, Lacabaratz-Porret C, et al.: CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004, 173:2410-248. This study demonstrates that HIV infection is associated with widespread activation of T cells, not just those specific for HIV.
9. Grossman Z, Meier-Schellersheim M, Sousa AE, et al.: CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002, 8:319-323.
10. Hazenberg MD, Otto SA, van Benthem BH, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17:1881-1888.
11. Tesselaar K, Arens R, van Schijndel GM, et al.: Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003, 4:49-54.
12. Suntharalingam G, Perry MR, Ward S, et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018-1028. This unfortunate and controversial study demonstrated that widespread non-antigen-specific T-cell activation in humans causes CD4+ T-cell depletion in the absence of HIV.
13. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
14. Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708-11717.
15. Mehandru S, Poles MA, Tenner-Racz K, et al.: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-770.
16. Giorgi JV, Majchrowicz MA, Johnson TD, et al.: Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998, 12:1833-1844.
17. Bleul CC, Wu L, Hoxie JA, et al.: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997, 94:1925-1930.
18. Wu L, Paxton WA, Kassam N, et al.: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681-1691.
19. Shattock RJ, Rizzardi GP, Hayes P, Griffin GE: Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect Dis 1996, 174:54-62.
20. Caiman AF, Busch MP, Vyas GN, et al.: Transcription and replication of human immunodeficiency virus-1 in B lymphocytes in vitro. AIDS 1988, 2:185-193.
21. Kawakami K, Scheidereit C, Roeder RG: Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A 1988, 85:4700-4704.
22. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ: Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
23. Schacker TW, Nguyen PL, Beilman GJ, et al.: Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002, 110:1133-1139.
24. Schacker TW, Reilly C, Beilman GJ, et al.: Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005, 19:2169-2171. This study demonstrated that lymphoid tissue fibrosis limits CD4+ T-cell restoration during antiretroviral therapy.
25. Schacker TW, Nguyen PL, Martinez E, et al.: Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002, 186:1092-1097.
26. Merrill JE, Koyanagi Y, Chen IS: Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989, 63:4404-4408.
27. Rieckmann P, Poli G, Fox CH, et al.: Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol 1991, 147:2922-2927.
28. Swingler S, Mann A, Jacque J, et al.: HIV-1 Nef mediates lymphocyte Chemotaxis and activation by infected macrophages. Nat Med 1999, 5:997-1003.
29. Schindler M, Munch J, Kutsch O, et al.: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067. This study highlights evolutionary changes in the accessory protein nef which may partly explain the ability of HIV to cause generalized T-cell activation and AIDS.
30. Eggena MP, Barugahare B, Jones N, et al.: Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005, 174:4407-4414. This study suggests that regulatory T-cell depletion during HIV infection might be a cause of generalized T-cell activation.
31. Matsuyama T, Kobayashi N, Yamamoto N: Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991, 5:1405-1417.
32. Brenchley JM, Price DA, Douek DC: HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006, 7:235-239. This review explains the hypothesis that the early loss of gut-associated lymphoid tissue-associated CD4+ T cells may allow for translocation of bacterial products, stimulating innate immune responses and causing generalized T-cell activation.
33. Lenkei R, Andersson B: High correlations of anti-CMV titers with lymphocyte activation status and CD57 antibody-binding capacity as estimated with three-color, quantitative flow cytometry in blood donors. Clin Immunol Immunopathol 1995, 77:131-138.
34. Valdez H, Anthony D, Farukhi F, et al.: Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000, 14:2239-2246.
35. Schacker T, Zeh J, Hu H, et al.: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718- 1725.
36. Giorgi JV, Hultin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870.
37. Giorgi JV, Lyles RH, Matud JL, et al.: Predictive value of immunologic and virologie markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002, 29:346-355.
38. Deeks SG, Kitchen CM, Liu L, et al.: Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004, 104:942-947.
39. Hunt PW, Martin JN, Sinclair E, et al.: T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534-1543.
40. Smith K, Aga E, Bosch RJ, et al.: Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004, 18:1953-1956.
41. Goicoechea M, Smith DM, Liu L, et al.: Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006, 194:29-37.
42. Benito JM, Lopez M, Lozano S, et al.: CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation. J Infect Dis 2005, 192:2142-2146.
43. Miller V, Phillips AN, Clotet B, et al.: Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002, 186:189-197.
44. Pitrak DL, Bolanos J, Hershow R, Novak RM: Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001, 15:1317-1319.
45. Deeks SG, Hoh R, Grant RM, et al: CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002, 185:315-323.
46. Sloand EM, Kumar PN, Kim S, et al.: Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999, 94:1021-1027.
47. Hunt PW, Deeks SG, Bangsberg DR, et al.: The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006, 20:691-699. This study demonstrates that some drug resistance mutations may decrease the ability of HIV to cause T-cell activation, independent of effects on viral replication.
48. Wyma DJ, Jiang J, Shi J, et al.: Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 2004, 78:3429-3435.
49. Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681-688.
50. Kaufmann GR, Bloch M, Finlayson R, et al.: The extent of HIV-1-related immunodeficiency and age predict the longterm CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002, 16:359-367.
51. Valdez H, Connick E, Smith KY, et al.: Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 16:1859-1866.
52. Davey RT Jr, Chaitt DG, Albert JM, et al.: A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179:849-858.
53. Davey RT Jr, Murphy RL, Graziano FM, et al.: Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000, 284:183-189.
54. Kovacs JA, Vogel S, Albert JM, et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350-1356.
55. Sereti I, Anthony KB, Martinez-Wilson H, et al.: IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104:775-780.
56. Sereti I, Imamichi H, Natarajan V, et al.: In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005, 115:1839-1847. This study demonstrates how IL-2 may paradoxically lead to sustained decreases in T-cell activation by expanding regulatory T cells, leading to sustained CD4+ T-cell expansion.
57. McComsey GA, Whalen CC, Mawhorter SD, et al.: Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001, 15:321-327.
58. Havlir DV, Gilbert PB, Bennett K, et al.: Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001, 15:1379-1388.
59. Calabrese LH, Lederman MM, Spritzler J, et al.: Placebo-controlled trial of cyclosporine-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002, 29:356-362.
60. Sankatsing SU, Jurriaans S, van Swieten P, et al.: Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004, 18:1925-1931.
61. Lederman MM, Smeaton L, Smith KY, et al.: Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis 2006, 194:1677-1685.